Cell-free DNA (cfDNA) is a subset of circulating extracellular DNA in plasma, which is released from cells mostly through apoptosis, necrosis, and active secretion [1]. The cfDNA is easily obtained by using minimally invasive procedures and has unique potential biomarkers for non-invasive prenatal testing and cancer management [2,3]. The recent advances in molecular technologies such as next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR) have enabled routine analysis in clinical laboratories [4]. The standardization of the analytical conditions to detect the genetic alterations in cfDNA still remains a major challenge [5]. After isolation from plasma, cfDNA is quantified before downstream analysis (e.g., NGS and dPCR). An accurate measurement of cfDNA, as a stringent quality control of cfDNA isolation, is a critical preliminary step for these downstream analyses [6]. Several methods have been described to quantify cfDNA. Quantitative PCR (qPCR) has been used to measure DNA concentration by targeting various pre-selected DNA sequences, and recently more rapid and costeffective methods such as spectrophotometry, fluorometry, and electrophoresis-based methods are being used [5].